Importantly, we demonstrate that genetic manipulation or therapeutic targeting of this receptor provides a novel strategy to reverse the resistance to TKI-induced ferroptosis in mouse and human HER2-positive breast cancer cells. This evidence concerns the gene ERBB2 and breast cancer.